3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
7
Sarcoma
2
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
4
Thymoma
1
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroblastoma
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Carcinoid Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
olaparib
1
lutetium Lu 177 dotatate
1
dactolisib
1
Quality of Life
1
Patient Reported Outcome Measures
1
PM 01183
1
Molecular Diagnostic Techniques
1
Irinotecan
1
Immunotherapy
1
Everolimus
1
Drug Therapy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
olaparib
×
NET
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled